費用・規模
- 経費率
- 0.7500%
- ベンダー値
- ベンダー記録日 2026-03-18
- 純資産総額
- $1.04B
- ベンダー値
- ベンダー記録日 2026-03-18
- 取得済み明細
- 30件
- 総数は未確認
- ベンダー記録日 2026-03-18
- 上位10銘柄の比率
- 59.47%
- 取得済み上位10件の合計
- ベンダー記録日 2026-03-18
$ 47.4
-
相対評価は未実施(比較対象・重みが未確定)
The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical market conditions, to equity securities issued by both domestic and international companies. These companies are strategically chosen from various sectors based on their direct connection to the fund's core investment principle: the groundbreaking genomics revolution.
| Ticker | Company | Weight |
|---|---|---|
| CRSP | Crispr Therapeutics AG | 9.54% |
| TEM | Tempus AI, Inc. Class A Comm… | 9.53% |
| TWST | Twist Bioscience Corp | 8.28% |
| TXG | 10X Genomics Inc | 5.58% |
| BEAM | Beam Therapeutics Inc | 5.27% |
| PSNL | Personalis Inc | 4.90% |
| NTRA | Natera Inc | 4.30% |
| ILMN | Illumina Inc | 4.21% |
| GH | Guardant Health Inc | 4.04% |
| RXRX | Recursion Pharmaceuticals In… | 3.83% |
| 銘柄 | 株価 | 配当利回り |
|---|